FDA hands down ap­proval for Bris­tol My­er­s' lung can­cer drug from Turn­ing Point buy­out

Bris­tol My­ers Squibb’s $4.1 bil­lion buy­out of Turn­ing Point Ther­a­peu­tics has paid off, with the FDA hand­ing down an ap­proval of the lead can­cer drug in the ac­qui­si­tion.

Re­potrec­tinib, which will now be mar­ket­ed as Aug­ty­ro, has been ap­proved for adult pa­tients with lo­cal­ly ad­vanced or metasta­t­ic ROS1-pos­i­tive non-small cell lung can­cer. It will be a new ri­val to Pfiz­er’s Xalko­ri and Roche’s Ro­z­lytrek in ROS1-pos­i­tive NSCLC.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.